ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
‘Future protect': shoring up clinical programs against changes in standard of care
Kristen Buck and David Morse weigh in on how to avoid some recent pitfalls seen at US FDA advisory committee panels.
Innovation in oncology clinical trials
Dr. Brian Huber, VP Drug Development & Consulting, discusses the shift from histology-based to lesion-based trial design in precision medicine.
Anatomic pathology in the digital era
Greg Cox, Director ICON Laboratory Services, shares his perspective on how integrating digital pathology into clinical trials can benefit study outcomes and data integrity.
Diversity and inclusion in clinical trials
Nuala Murphy, President of Clinical Research Services, discusses the need for diversity and inclusion in clinical trials.
Trailblazing women stress importance of diversity in pharma
Nuala Murphy, President of Clinical Research Services at ICON, discusses how increasing diversity is a key area of focus for ICON, both in terms of patient diversity and diversity in the organisation.
Has the pandemic enabled us to accelerate the pace of drug development?
Nuala Murphy, President Global Specialty Solutions, contributes to this Marvellous Medicine BBC4 podcast about accelerating the pace of drug development due to the pandemic.
The central role of Interactive Response Technology in today's clinical trials
Michelle Lynskey, Global Head of Interactive Response Technology and Clinical Supplies Management, offers her insights on the role of IRT in clinical trials.
A trusted partner for clinical development
ICON CEO Steve Cutler chats with Newsweek, on ICON’s role in the development of much needed medicines. The interview (page 12 of PDF) is part of a special report on Ireland.
The pursuit of patient diversity in clinical trials
Nuala Murphy, President of Clinical Research Services, provides expert commentary on the importance of patient diversity in clinical trials.
The tangled web of large outsourced providers
ICON’s $12 billion acquisition of PRA Health Sciences is discussed as part of the changing CRO landscape.